CANbridge Acquires Rare Liver Disease Drug in $120 Million Agreement

CANbridge Pharma of Beijing has acquired Greater China rights to develop maralixibat, a treatment for a set of rare inherited childhood liver diseases caused by impaired bile flow. Mirum Pharma is developing maralixibat, a clinical-stage oral medication, for Alagille syndrome, progressive familial intrahepatic cholestasis and biliary atresia. CANbridge will pay $11 million upfront and be responsible for $109 million in milestones, plus royalties. It will also oversee Mirum’s clinical sites in China to accelerate enrollment of a global Phase IIb maralixibat test for biliary atresia. More details.... Stock Symbol: (NSDQ: MIRM) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.